| Objective:To analyze the expression of GPER1 in lung adenocarcinoma,and the relati onship between GPER1 and clinicopathological characteristics was elucidated,a nd further discuss the effect of gperl expression in cytoplasm and nucleus of 1 ung adenocarcinoma on the therapeutic effect of EGFR-TKI.Methods:Collect 68 paraffin tissue specimens from thoracic surgery in Yan’an Hospital affiliated to Kunming Medical University and pathologically diagnosed as lung adenocarcinoma.Immunohistochemistry(IHC)was used to detect the expression of GPER1 and the location of GPER1 in cells;2.Next-generation gene sequencing was used to detect EGFR mutations,and the χ2 test was used to analyze the relationship between GPER1 and EGFR and clinicopathological characteristics.The expression of GPER1 was further silenced by lentiviral transfection of PC-9 cells,and Western blot was used to detect the presence of GPER1.Knockdown level in lung adenocarcinoma PC-9;cell counting kit-8(Cell Counting Kit-8,CCK-8)was used to detect GPER1 knockdown on lung adenocarcinoma PC-9 cell proliferation and sensitivity to gefitinib,immunofluorescence method to detect the expression and location of GPER1 in PC-9 cells.Results:1.The positive expression rate of GPER1 in human lung adenocarcinoma tissue is 64.7%,the lymph node metastasis rate of cases is 47.06%(32/68),of which 70.83%(25/32)of lymph node metastasis cases are positive for GPER1,which is significantly higher than 52.78.%(19/36)(P=0.029)in the non-metastasis group of lymph nodes;the positive expression rate of GPER1 in stage Ⅲ-Ⅳ was 86.1%(31/36),which was significantly higher than 40.63%in stage Ⅰ-Ⅱ(13/32)(P<0.05);The mutation rate of EGFR with positive GPER1 expression was 75.00%(P>0.05).There was no significant difference between GPER1 expression and patient gender,age,tumor size,and smoking(P>0.05).2.The mutation rate of EGFR in patients with lung adenocarcinoma is 58.82%,and the mutation rate of EGFR in women is 70.73%(29/41),which is significantly higher than 40.74%(11/27)in men.The EGFR mutation rate of non-smokers is higher than that of smoking patients.The EGFR mutation rate of non-smokers is 72.09%(31/43),and the mutation rate of smoking patients is 36.00%(9/25).EGFR mutations are related to the patient’s age,tumor size,and lymph nodes.There was no correlation between metastasis and tumor TNM staging(P>0.05).3.GPER1 is mainly expressed in the nucleus of lung adenocarcinoma tissues.When GPER1 is expressed in the cytoplasm,the nucleus is generally also expressed.3.GPER1 is mainly expressed in the nucleus of lung adenocarcinoma tissue.When GPER1 is expressed in the cytoplasm,the nucleus also expresses GPER1.4.The expression of GPER1 may enhance the sensitivity of lung adenocarcinoma to EGFR-TKI,and this effect is especially obvious when GPER1 is expressed in the nucleus.5.Lentivirus was transfected into lung adenocarcinoma cells PC-9 to silence the expression of GPER1.The morphology of PC-9 cells after GPER1 knockdown did not change significantly.6.After the expression of GPER1 in lung adenocarcinoma PC-9 cells is down-regulated,the proliferation activity of PC-9 cells decreases,but the sensitivity to gefitinib increases.7.GPER1 in lung adenocarcinoma PC-9 cells is mainly expressed in the nucleus.Conclusions:1.GPER1 is highly expressed in patients with advanced lung adenocarcinoma and lymph node positive and EGFR mutations;2.GPER1 is widely expressed in lung adenocarcinoma tissues,and GPER1 is required for the proliferation of lung adenocarcinoma;3.The expression of GPER1 may enhance the sensitivity of lung adenocarcinoma to EGFR-TKI,and this effect is particularly obvious when GPER1 is expressed in the nucleus;4.GPER1 may be an expression marker of lung cancer,and the expression of GPER1 can be used as one of the indicators to predict the efficacy of EGFR-TKI treatment. |
PDF Full Text Request